Stay updated on Pembrolizumab for Intermediate Risk NMIBC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The page now lists Revision: v3.4.2 and no longer lists Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-13T12:55:02.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Added Revision: v3.4.1; removed Bladder cancer, related topics MedlinePlus Genetics, and Revision: v3.4.0.
    Difference
    0.2%
    Check dated 2026-02-06T09:10:48.000Z thumbnail image
  4. Check
    33 days ago
    Change Detected
    Summary
    Show Glossary and Hide Glossary options were added. Metadata labels were updated with 'Last Update Submitted that Met QC Criteria' and a new 'Revision: v3.4.0' tag, and capitalization of 'No FEAR Act Data' was standardized.
    Difference
    0.3%
    Check dated 2026-01-22T17:58:00.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Revision label updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-15T10:53:26.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    Added related topic tags 'Bladder cancer' and 'MedlinePlus Genetics' to the page, which are minor metadata enhancements and do not modify study details or user interactions. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-12-25T02:32:12.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    A new Locations section lists Hampshire, Oxfordshire, and Surrey, and the page revision updated to v3.3.3. The standalone Hampshire/Oxfordshire/Surrey Locations subsections and the HHS Vulnerability Disclosure link were removed.
    Difference
    0.4%
    Check dated 2025-12-17T20:31:21.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Intermediate Risk NMIBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.